Transthyretin Amyloidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Transthyretin Amyloidosis Market Outlook

Thelansis’s “Transthyretin Amyloidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Transthyretin Amyloidosis   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Transthyretin Amyloidosis Overview

Amyloidosis is a systemic infiltrative disease characterized by depositing insoluble proteins outside cells. Transthyretin Amyloidosis occurs when a toxic substance called amyloid is deposited in the extracellular space of the heart. Amyloid consists of abnormally folded proteins and other matrix-forming components such as proteoglycans, glycosaminoglycans, collagen, and laminin. These misfolded proteins originate from amyloid light (AL) chain proteins and amyloid transthyretin (ATTR). It may manifest primarily or be discovered incidentally in patients with other signs and symptoms of systemic amyloidosis. Following are the various etiological types of Transthyretin Amyloidosis:

1. Primary amyloidosis (also known as amyloid light chain amyloidosis or AL amyloidosis) is caused by the deposition of AL fibrils produced by abnormal plasma cells in individuals with plasma cell dyscrasia, such as multiple myeloma.
2. Secondary amyloidosis (AA amyloidosis) is caused by the deposition of serum amyloid A, an inflammatory protein produced in chronic inflammation conditions.
3. Senile systemic amyloidosis (also known as wild transthyretin or ATTRw) is caused by age-related amyloid deposition, which consists of normal transport-thyroxine-and-retinol (TTR) protein. This is the most common type of Transthyretin Amyloidosis.
4. Mutant TTR causes familial amyloidosis (ATTRm).
5. Isolated atrial amyloidosis is caused by the deposition of amyloid derived from the atrial natriuretic peptide.

Deposing amyloid in the heart can lead to various heart diseases through multiple mechanisms. Direct infiltration of the interstitial space increases the ventricular walls’ thickness and stiffness, leading to ventricular diastolic dysfunction. In AL amyloidosis, amyloid deposition in arterioles can cause angina or, rarely, myocardial infarction. Amyloid infiltration in the atria can induce structural changes, providing a substrate for atrial fibrillation. The prognosis varies depending on the specific type of Transthyretin Amyloidosis. The average survival time in untreated patients is as follows: AL (primary) amyloidosis ranges from 9 to 24 months, ATTR familial amyloidosis from 7 to 10 years, senile amyloidosis from 5 to 7 years, and AA (secondary) amyloidosis is more than ten years.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Transthyretin Amyloidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034